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ABSTRACT
Clear cell Renal Cell Carcinoma (ccRCC) formation is connected to functional loss 
of the von Hippel-Lindau (VHL) gene. Recent data identified its gene product, pVHL, 
as a multifunctional adaptor protein which interacts with HIFα subunits but also with 
the tumor suppressor p53. p53 is hardly expressed and rarely mutated in most ccRCC. 
We showed that low and absent p53 expression correlated with the severity of VHL 
mutations in 262 analyzed ccRCC tissues. In contrast to nonsense and frameshift 
mutations which abrogate virtually all pVHL functions, missense mutations may 
rather influence one or few functions. Therefore, we focused on four VHL missense 
mutations, which affect the overlapping pVHL binding sites of p53 and Elongin C, by 
investigating their impact on HIFα degradation, p53 expression and signaling, as 
well as on cellular behavior using ccRCC cell lines and tissues. TP53 mRNA and its 
effector targets p21, Bax and Noxa, were altered both in engineered cell lines and in 
tumor tissues which carried the same missense mutations. Two of these mutations 
were not able to degrade HIFα whereas the remaining two mutations led to HIFα 
downregulation, suggesting the latter are p53 binding site-specific. The selected 
VHL missense mutations further enhanced tumor cell survival, but had no effects on 
cell proliferation. Whereas Sunitinib was able to efficiently reduce cell proliferation, 
Camptothecin was additionally able to increase apoptotic activity of the tumor cells. 
It is concluded that systematic characterization of the VHL mutation status may help 
optimizing targeted therapy for patients with metastatic ccRCC.
INTRODUCTION
Renal cell carcinoma (RCC) is one of the most 
common cancer types worldwide with clear cell RCC 
(ccRCC) being the most frequent and aggressive RCC 
subtype [1, 2]. In ccRCC the von Hippel-Lindau tumor 
suppressor gene (VHL) is frequently altered by deletion of 
one allele (90%) and promoter methylation (up to 20%) 
or mutations (70-80%) of the other. VHL inactivation 
is considered as a critical part of tumor initiation [3-5]. 
In addition to its well-known function as E3 ubiquitin 
ligase for ubiquitination and proteasomal degradation of 
hypoxia-inducible factor subunits (HIF1α and HIF2α) [6-
8], the VHL protein (pVHL) has been recently identified 
as a multiadaptor protein involved in a variety of cellular 
processes such as microtubule stability, activation of p53, 
neuronal apoptosis, cellular senescence and aneuploidy, 
ubiquitination of RNA polymerase II and regulation of 
NFkB activity [1].
Given different types of VHL mutations, a deeper 
insight in the biological effects of VHL mutations may allow 
a better prediction of ccRCC prognosis. In particular, VHL 
loss-of-function mutations (LOF) (frameshift, nonsense 
and splice site mutations) highly likely abrogate pVHL 
function, whereas the consequences of missense mutations on 
pVHL stability and target binding ability are rather unclear. 
Missense mutations may provoke diverse effects on pVHL 
interactions with binding partners, thus exerting different 
impact on pathways normally regulated by pVHL. This was 
shown for HIF1α and HIF2α degradation [9] as well as for 
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other pVHL binding partners, including Jade1, RPB1, VDU1, 
EEF1A1 and CCT-ζ-2, for which loss of binding capability 
upon missense mutations was demonstrated [10-15].
p53 is a well-known tumor suppressor gene, whose 
activation by hypoxia or DNA damage leads to cell cycle 
arrest, DNA repair and apoptosis. Under cellular stress, 
p53 level is increased by inhibition of its interaction with 
MDM2 and activated by post-translational modifications 
through different regulators which lead to transactivation 
of its downstream target genes p21 (alias CDKN1A, 
growth arrest), Bax and Noxa (apoptosis) [16]. The role 
of p53 in ccRCC and its relation to pVHL is yet unclear. 
Two previous studies showed that pVHL can stabilize 
p53 and enhance its transcriptional activity [17, 18] 
whereas another study found that p53 expression is not 
pVHL-dependent [19]. In addition, pVHL inactivation in 
RCC cells lead to decreased apoptosis [20], which may 
be explained by the lack of phosphorylation of pVHL by 
checkpoint-kinase 2, impairing the recruitment of p53 
coactivators (such as p300 and Tip60) [21].
Tumors with p53 mutations are known to be 
associated with chemoresistance [22]. p53 is one of the most 
frequently mutated genes in several cancers [23], but p53 
mutations are rare in ccRCC [24-26]. Interestingly, ccRCC 
is resistant to chemotherapy and Gurova et al. suggested 
that p53 signaling is repressed by mechanisms independent 
of p53 mutations [27]. ccRCC is currently treated with anti-
angiogenic drugs, such as the Tyrosine-Kinase-Inhibitors 
(TKI) Sorafenib and Sunitinib, to counter the effects of the 
HIF1/2α accumulation occurring upon pVHL inactivation. 
The efficiency of this therapeutic strategy is still suboptimal 
[28]. As shown for colorectal cancer where p53 negative 
cells were less responsive to anti-angiogenic treatment than 
wild-type p53 cells [29], alteration of p53 signaling may 
also be an explanation for the low response rate in ccRCC.
We hypothesized that VHL missense mutations 
occurring in the p53 binding domain of pVHL lead to 
deficient p53 transactivation and/or promote HIF1α and 
HIF2α accumulation, thus impacting tumor behavior and 
response to treatment. In this study, we investigated four 
different missense mutations located in the p53 binding 
site (codons 154-163), which is overlapping with the 
ElonginC binding domain (codons 157-171). Due to this 
overlap, the missense mutations investigated could have 
an impact on p53 signaling and/or on HIF1/2α degradation 
through an altered binding to ElonginC. Our goal was to 
evaluate the selected missense mutations effectiveness 
in HIF1/2α degradation, p53 transactivation, and their 
response to chemotherapy and TKI.
RESULTS
Expression of p53 in ccRCC
Pathological and molecular characteristics of 
renal cell cancers on the tissue microarray (TMA) were 
previously described [9, 30]. In brief, the TMA consisted 
of 262 clear cell, 48 papillary (24 type I, 24 type II), 
15 chromophobe RCC, eight non specified RCC, 22 
oncocytoma and 28 normal tissue cores. 181 of 262 
ccRCC were VHL mutated (69%).
TMA analysis revealed absent or only low p53 
expression in most ccRCC (76%), and chromophobe RCC 
(80%), whereas nuclear p53 positivity was high in about 
60% of papillary RCC (Figure 1A). By separating the 262 
ccRCC in VHL wild-type and VHL mutated tumors, we 
observed that p53 expression was less frequent in tumors 
with VHL alterations (p=0.0212) (Figure 1B). Notably, the 
p53 expression frequency decreased with the predicted 
impact of mutations on the function of pVHL (Figure 1C).
Selection of mutations in the p53/EloC binding 
domains of pVHL
The binding domains of p53 and EloC are 
located between codons 154 to 163 and 157 to 171, 
respectively [34]. Among 254 VHL mutations found in 
360 ccRCC tissue specimen (70.6%), 25 (9.8%) resided 
in these binding domains. Eleven (4.3%) were missense 
mutations causing an amino acid exchange. Eight 
missense mutations were predicted to destabilize pVHL 
and three missense mutations had no or little impact on 
pVHL stability.
For this study, we selected four out of 11 missense 
mutations occurring in the p53/EloC binding domain for 
further analysis. Three were predicted to have mild impact 
on pVHL (Leu158Val, Arg161Gln, and Cys162Arg) 
and one was predicted to highly destabilize pVHL 
(Arg161Pro). Two other missense mutations occurring in 
the HIF1/2α binding domain (Tyr98His, Tyr98Asn), as 
well as one nonsense mutation located in the p53/EloC 
binding domain (Arg161X) were predicted to differently 
impair HIF1/2α degradation pathway and were used as 
controls for the cell line experiments (summarized in 
Table 1).
Effects of selected VHL mutations on HIF1/2α 
and p53
The established stable cell lines were investigated 
by Western Blot for the effects of the VHL missense 
mutations on HIF1/2α degradation and the two HIF1/2α 
targets CAIX and Glut1 (Figure 2). As expected, pVHL 
was undetectable in RCC4 Babe and RCC4 Arg161X. 
HIF1α and 2α were stabilized in RCC4 Babe, Arg161Pro, 
Arg161X, and also in RCC4 Cys162Arg. RCC4 
Arg161Gln, Tyr98His and Tyr98Asn showed partial HIF1α 
and 2α degradation. HIF1/2α strong degradation was 
seen in Leu158Val which was similar to RCC4 VHL30 
(wild-type). CAIX and Glut1 expression correlated with 
HIF1/2α. No clear difference in p53 expression was seen 
between VHL wild-type and mutated cell lines.
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Impact of VHL mutations on p53 downstream 
targets in cell lines
Previous studies showed that pVHL enhances p53 
transcriptional activity which was reduced by Ser111Arg 
or Ser111Cys missense mutations [19, 23]. Here we 
studied the effects of our selected VHL mutations on 
the RNA level of TP53 and its effectors p21, Bax and 
Noxa. The transcription levels of TP53, p21 and Noxa 
in cells expressing the different mutant forms were 
generally lower compared to the wild-type form of pVHL 
(Figure 3). Transcription levels of p21 and Noxa were 
significantly reduced in most VHL mutants compared to 
RCC4 expressing VHL wild-type. Bax RNA levels were 
lower only in RCC4 Leu158Val and Arg161Gln. Among 
the missense mutations in the p53 binding domain, no 
significant difference in RNA levels was seen between the 
three non-destabilizing/slightly destabilizing mutants and 
the one with destabilizing effects on pVHL.
Impact of VHL mutations on p53 downstream 
targets in tissues
Nine ccRCC tissues (one VHL wild-type, two with 
mutation Leu158Val (#1, #2), one with Arg161Gln, one 
with Cys162Arg, one with Arg161Pro, one with Tyr98Asn 
and two with Arg161X (#1, #2)) and three normal kidney 
tissues were investigated for RNA expression of VHL, 
TP53 and its downstream targets. TP53, p21, Bax and 
Noxa RNA levels relative to VHL were compared in three 
normal tissues and in one VHL wild-type ccRCC. TP53, 
p21, Bax and Noxa expression levels in tumor tissue were 
similar to the ones seen in normal tissues (Figure 4). The 
RNA levels of TP53 and its downstream targets relative 
to VHL transcription levels were assessed in ccRCC 
samples expressing the mutant forms of VHL (Figure 5). 
Similarly to the established cell lines, wild-type VHL 
tumor showed generally higher RNA levels of TP53 and 
its downstream targets than VHL mutated tumors. All eight 
mutant samples showed a decrease of p21, Bax and Noxa 
RNA levels compared to VHL wild-type except for Noxa 
in the Cys162Arg mutated tumor. VHL missense mutations 
located in the p53 binding domain and VHL mutations 
in the HIF1/2α binding domain were similarly affected 
in p53 signaling. Notably, no significant differences in 
the RNA levels were observed between the mutation 
Arg161Pro which highly destabilize pVHL and the other 
mutations which are predicted to have a lower impact on 
pVHL stability.
Influence of HIF1α on p53 signaling
Since it is known that HIF1α can negatively regulate 
p53 activity [31, 32], we next asked whether impaired p53 
signaling was directly linked to VHL mutation status or 
was a consequence of the deregulated pVHL/HIF1α axis. 
For this purpose, RCC4 cells with re-expressing VHL 
wild-type and with deficient VHL were transfected with 
a small hairpin RNA for HIF1α knockdown (Figure 6). 
HIF1α knockdown led to upregulation of TP53, p21, 
Bax and Noxa transcription in VHL wild-type and VHL 
deficient cell lines. This effect was significant for all 
targets in the absence of functional pVHL and no or little 
difference was seen in VHL expressing cell lines. Cell 
lines expressing functional pVHL showed higher RNA 
levels for all targets compared to pVHL deficient cell 
lines. These results suggest that the functional integrity of 
pVHL has a dominating impact on p53 signaling.
Figure 1: A. p53 protein expression in RCC tissue; B. p53 protein expression in ccRCC and VHL mutation status; and C. p53 protein 
expression in ccRCC and mutation impact on pVHL stability. Wt: VHL wild type; Mild impact: Destabilizing or neutral or stabilizing; High 
impact: highly stabilizing or highly destabilizing; LOF (Loss of Function): Frameshift and nonsense mutations. p-value: *<0.05, **<0.01, 
***<0.001
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p21 expression in ccRCC tumor tissues
The RCC TMA which was analyzed for p53 
expression was also immunostained against p21 to 
correlate p21 expression with the VHL mutation status and 
p53 expression. ccRCC with LOF mutations expressed 
less p21 than VHL wild-type tumors (not significant) and 
missense mutated tumors (p<0.05) (Figure 7A). About 
10% of the p53 negative and 52% of the p53 positive cores 
showed a high content of p21 (p<0.0001). The expression 
pattern of p53 and p21 is significantly different in VHL 
LOF ccRCC compared to missense (p=0.0288) and wild-
type cases (p<0.0001) (Figure 7B). The tumors positive 
for both p53 and p21 were less frequent in VHL LOF 
ccRCC than in wild-type cases (p=0.0327).
Effects of p53 and HIF1/2α binding site-
specific VHL mutations on apoptosis and cell 
proliferation
The apoptotic behavior of cells expressing different 
VHL missense mutations was evaluated by Caspase 3/7 assay. 
All pVHL mutants were deficient in apoptosis compared to 
VHL wild- type (Figure 8A). Cells with p53 binding site-
specific VHL mutations showed significantly lower apoptotic 
activity than those with mutations that affected the HIF1/2α 
binding domain (p=0.0088) (Figure 8B). In contrast, cell 
proliferation was not influenced by the different binding site-
specific VHL mutants (Figure 8C-8D).
Apoptotic and proliferative behavior of cells 
upon treatment with Camptothecin and/or 
Sunitinib
Camptothecin, which stabilizes and activates p53, 
was applied to the stable cell lines alone or in combination 
with Sunitinib. Whereas Sunitinib affects the proliferation 
pathway, Camptothecin is known to affect both apoptosis 
and proliferation [33-35]. As expected, treatment with 
Camptothecin alone or in combination with Sunitinib 
highly increased apoptosis in all cell lines, whereas 
Sunitinib alone had no effect on apoptosis. Cells with 
Arg161Gln, Arg161Pro and Tyr98Asn showed the highest 
response to Camptothecin alone. Apoptosis was even 
increased with combined treatment in Arg161Gln and 
Tyr98Asn cells (Figure 9A).
An effect on cell proliferation was observed when 
the cells were treated with all three treatment strategies. 
With the exception of Arg161X, cell proliferation was 
decreased between 30-75% (Figure 9B). The response 
to the different treatments was similar for cell lines with 
missense mutation in the p53 binding domain and in the 
HIF1/2α binding domain.
DISCUSSION
By investigating p53 expression in 262 ccRCC, we 
saw a relationship between p53 expression and the severity 
of VHL mutations. Our results are consistent with other 
studies showing that p53 expression was significantly 
lower in ccRCC than in other RCC subtypes [36-39]. The 
correlation between severe VHL mutations and negative or 
low p53 expression suggests a close relationship between 
loss of function of pVHL and disturbed p53 signaling in 
ccRCC.
As the location of a VHL missense mutation may 
specifically affect one of the many binding sites of pVHL, 
we focused on those missense mutations that alter the 
p53 binding site. Therefore, we selected four missense 
mutations identified in the p53 binding domain. The 
missense mutations were predicted to have different effects 
on pVHL stability, from highly destabilizing to neutral. [9]. 
Table 1: Cell lines with VHL-expressing vector constructs, predicted effects on pVHL stability and affected binding 
domains of pVHL
RCC4 cell lines stably expressing: Predicted effect Binding domain affected
Babe (Ser65Trp) destabilizing and cause protein 
malfunction
others
VHL30 none none
Leu158Val slightly destabilizing p53/EloC
Arg161Gln neutral p53/EloC
Cys162Arg neutral p53/EloC
Arg161Pro destabilizing and cause protein 
malfunction
p53/EloC
Tyr98His neutral HIF1/2α
Tyr98Asn destabilizing HIF1/2α
Arg161X Loss of function HIF1/2α/p53/EloC
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As the p53 binding domain overlaps the ElonginC binding 
domain [17], the missense mutations in this region should 
affect pVHL interactions with p53 and/or HIF1/2α.
The VHL mutations Cys162Arg, Arg161Pro and 
Arg161X were unable to downregulate HIF1/2α at the 
protein level. This result was expected for the nonsense 
mutation Arg161X and for Arg161Pro due to its predicted 
destabilizing effect on pVHL stability but not for 
Cys162Arg which is predicted to be neutral. As it was 
demonstrated for the missense mutations Cys162Phe and 
Figure 2: A. and B. Western blots showing pVHL, p53, HIF1/2α and HIF1/2α targets expression (CAIX and Glut1) in the established 
stable cell lines.
Figure 3: mRNA levels of TP53, p21, Bax, and Noxa in the established RCC4 stable cell lines. For each gene the mRNA 
level of the VHL30 sample was used as reference and compared to the mRNA levels in the other cell lines. p-value: *<0.05, **<0.01 (data 
are presented as mean +SEM).
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Cys162Ala [40, 41], Cys162Arg also seems to impair 
ElonginC binding, thus leading to HIF1/2α accumulation. 
Mutant Arg161Gln remained only partly functional 
for HIF1/2α degradation but like VHL30 (wild-type), 
Leu158Val was able to fully downregulate HIF1/2α. 
Notably, Arg161Gln had a milder effect on HIF1α 
degradation than on HIF2α. In contrast to HIF1/2α, p53 
expression was hardly affected by the VHL mutations. 
Figure 5: mRNA levels of TP53, p21, Bax, Noxa relative to VHL wild type transcription levels in ccRCC tissue samples 
carrying the VHL mutations selected for cell line experiments. No tissue with VHL mutation Ser65Trp (endogenous mutation 
of RCC4) and Tyr98His was available in our cohort. For each target the mRNA level of the VHL wild-type tumor is used as reference and 
compared to the mRNA levels in the other tumors. p-value: *<0.05, **<0.01, ***<0.001 (data are presented as mean +SEM)
Figure 4: mRNA levels of TP53, p21, Bax, Noxa relative to VHL transcription levels in three normal kidney tissues and 
one VHL wild-type ccRCC (data are presented as mean +SEM).
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In a previous study it was shown that pVHL wild-type 
enhances p53 transcriptional activity for its downstream 
targets p21 and Bax [17]. We hypothesized that VHL 
mutations could affect p53 activity rather than stability 
in our stable cell lines. Therefore, we analyzed the 
transcription levels of TP53 and its downstream targets 
p21, Bax and Noxa.
The RNA levels of TP53, p21 and Noxa were 
lower in all VHL mutant cell lines compared to those in 
RCC4 VHL30. Bax RNA levels were affected to a lesser 
Figure 7: A. p21 protein expression in ccRCC tissue and VHL mutation type; B. p53/p21 combined expression and VHL mutation type. 
Wt: wild-type, ms: missense, LOF: Loss of function. p-value: *<0.05, **<0.01, ***<0.001
Figure 6: mRNA levels of TP53, p21, Bax and Noxa in RCC4 expressing VHL (white), VHL deficient (grey), and 
corresponding HIF1α knockdown (patterned). p-value: *<0.05, **<0.01, ***<0.001, ****<0.0001 (data are presented as mean 
+SEM).
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extent. We also analyzed the RNA levels in normal kidney 
and ccRCC tissue. p53 signaling was similar in VHL 
wild-type ccRCC and in normal tissue. In VHL mutated 
tumors RNA levels of TP53, p21, Bax and Noxa were 
significantly lower than in tumors with VHL wild-type, 
which confirmed the results obtained from the cell lines.
Recent findings suggest complex regulation between 
p53 and HIF1α. p53 has been described to bind HIF1α 
[32] which negatively affects its stability and activity 
[31]. Our results demonstrated that HIF1α knockdown 
led to an upregulation of TP53 and its downstream targets 
in both pVHL re-expressing and pVHL deficient RCC4. 
However, the RCC4 cell lines expressing VHL presented 
significantly higher RNA levels of TP53, p21, Bax and 
Noxa compared to the RCC4 pVHL-deficient cell lines, 
independently of HIF1α knockdown. This led us to the 
conclusion that pVHL is able to promote p53 signaling 
even in the presence of HIF1α.
To further prove the association of VHL mutation 
status with p53 signaling on the protein level in ccRCC 
tissue, we investigated the expression of the p53 
downstream target p21 by immunohistochemistry on the 
same TMA that was stained for p53. p21 was expressed 
in only 22% of ccRCC. Similarly to p53, p21 expression 
Figure 8: Effects of VHL mutations on apoptosis and cell proliferation. A. Apoptotic behavior of VHL wild type and mutated 
RCC4 cells; B. apoptotic behavior of RCC4 with missense mutations in the p53 and HIF1/2α binding domains; C. Proliferative behavior 
of VHL wild type and mutated RCC4 cells; D: Proliferative behavior of RCC4 with missense mutations in the p53 and HIF1/2α binding 
domains. VHL30 expression was used as reference and compared to the other cell lines. p-value: *<0.05, **<0.01 (data are presented as 
mean +SEM).
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Figure 9: A. Apoptotic and B. proliferative behavior of VHL wt and mutated RCC4 cells after treatment with Camptothecin, Camptothecin 
and Sunitinib (Combination), and Sunitinib. Signals after treatment of each cell line were normalized with corresponding mock signals 
(without treatment). VHL30 was used as reference and compared to the other cell lines. p-value: *<0.05, **<0.01 (data are presented as 
mean +SEM).
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was significantly lower in VHL LOF mutants compared 
to wild-type, thus supporting a potential role of pVHL’s 
integrity in sustaining functional p53 signaling.
At least 12 p53 isoforms have been reported in the 
literature [42] and their abnormal expression was observed 
in a wide range of cancers, including RCC [43, 44]. The 
p53 antibody (clone DO-7) used in our study detects wild 
type p53, p53β and p53γ. Therefore, it cannot be excluded 
that tumors exclusively expressing other p53 isoforms 
may have been missed. However, mRNA expression data 
of the different p53 isoforms demonstrated that p53, p53β 
and p53γ are the main expressed isoforms in RCC [43, 
44] suggesting minor impacts of p53 isoform expression 
on our results.
All our selected VHL mutations led to an 
attenuated apoptosis compared to VHL wild-type, but no 
significant change in cell proliferation was seen. Given 
their apoptosis deficiency, VHL mutant cells seem to 
have a survival advantage compared to VHL wild-type 
cells. However, cells with a missense mutation in the 
p53 binding domain were less apoptotic than cells with 
missense mutations affecting the HIF1/2α binding domain. 
Since VHL mutant cells affected apoptosis rather than cell 
proliferation, we treated the cells both with Camptothecin, 
a chemotherapeutic drug that stabilizes and activates p53 
by inducing DNA damage and decreases cell proliferation 
and Sunitinib, a TKI which negatively influences cell 
proliferation and is used to treat ccRCC. Notably, 
Camptothecin was more effective than Sunitinib because 
it decreased cell proliferation and increased apoptosis 
in all VHL mutated cell lines. However, the missense 
mutation location and the affected binding domains may 
only partially explain the differing response to treatment. 
In a previous study, the VHL mutants S111R and S111C, 
which are located in the HIF1/2α binding domain showed 
a decrease in apoptosis compared to VHL wild-type via 
impairment of recruitment of coactivators p300 and Tip60 
[21]. The loss of ability to recruit coactivators of p53 may 
explain the low apoptotic activity of our cell lines with 
VHL missense mutations located in the HIF1/2α binding 
domain.
In summary, we found an association of the VHL 
mutation type and p53 signaling, which was reflected by 
apoptotic deficiency. We also showed that pVHL integrity 
had a dominant effect over HIF1α downregulation in 
enhancing p53 transactivation suggesting disturbed 
p53 signaling is provoked by mutant pVHL rather than 
altered pVHL/HIFα axis. Notably, two VHL missense 
mutations in the p53 binding domain, Leu158Val and 
Arg161Gln, altered p53 signaling but retained HIF1/2α 
degradation function, thus confirming our hypothesis 
of differing effects of missense mutations on pVHL 
functions (summarized in figure 10) Our results may 
scrutinize the rationale of the systematic use of anti-
Figure 10: Comparison of predicted effects and own data of VHL mutations affecting the p53 and the HIF1/2α binding 
sites of pVHL and possible treatment strategies.
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angiogenic drugs, particularly for those metastatic ccRCC 
with VHL missense mutations that specifically affect non 
HIF1/2α binding sites. A systematic characterization of 
VHL mutations may help optimizing targeted therapy 
approaches for patients with metastatic ccRCC.
MATERIAL AND METHODS
Tissue Microarray and immunohistochemistry
A TMA [45] was stained using the mouse antibody 
p53 (clone DO-7, dilution 1:150, Dako A/S). As the 
tumors either showed hardly any or clearly more than 
ten positive nuclei, cores with up to five nuclei positive 
for p53 were grouped into “Low content” category and 
cores showing at least six positive nuclei were grouped 
into “High content”. The TMA was also stained and 
analyzed for p21 using the rabbit antibody p21 (C-19) (sc-
397, dilution 1:50, Santa-Cruz Biotechnology) and scored 
following the same criteria used for p53.
In silico selection of VHL mutations
We used the Site Directed Mutator in silico tool 
[46] to characterize VHL missense mutations in 360 
FFPE ccRCC samples [47] which were re-reviewed 
by two pathologists (H.M., E.D.) according to the new 
WHO/ISUP grading system [48] (Table 2). The program 
calculates the thermodynamic change (ddG) occurring 
after modification of one amino acid according to the 
main chain conformation, solvent accessibility and 
hydrogen bonding class. The missense mutations were 
then classified as follows:
- ddg < -2.0 or >2.0: highly destabilizing or 
stabilizing referred as “high impact”
- -2.0 ≤ ddg < 2.0: (slightly) destabilizing, neutral, 
(slightly) stabilizing referred as “mild impact”
The binding domains of HIF1/2α (amino acid 67-
117), p53 (aa 154-163) and Elongin C (aa 157-171) were 
assessed as described by Leonardi et al. [49]. We selected 
four mutations that were located in the overlap of p53 and 
EloC binding domains of pVHL (aa 157-163): three were 
predicted to have no or little impact on the protein stability 
(Leu158Val, Arg161Gln, Cys162Arg, mild impact) and 
one was predicted to highly destabilize pVHL (Arg161Pro, 
high impact). Controls located in the HIF1/2α binding 
domain (Tyr98His, Tyr98Asn) and one nonsense mutation 
(Arg161X) were also included.
Knock down, transfection and transduction 
experiments
The pVHL deficient cell line RCC4 (expressing 
VHL Ser65Trp, highly destabilizing mutation) was 
kindly provided by W. Krek (ETH Zurich, Switzerland) 
and grown under conditions recommended by ATCC. 
This cell line has been authenticated as RCC4 plus 
vector alone (ECACC 03112702) in June 2016. A 
pcDNA3.1 vector encoding VHL wild-type [9] was 
used to generate the selected mutants with the Quick 
Change Lightning site-directed mutagenesis kit (Agilent 
technologies, United States). Subsequently, pcDNA3.1 
was subcloned into pBabe vectors for transduction in 
mammalian cells.
pBabe empty vector and vectors containing the 
VHL wild-type or the mutant VHL sequences were 
transfected into Platinum-A Retroviral Packaging Cell 
Line (Cell Biolabs, United States) for viral pseudo-
particles production according to the X-tremeGENE 
9 DNA Transfection Reagent 3:1 protocol (Roche 
Diagnostics, Switzerland). The viral supernatant 
was collected and applied to RCC4 for transduction 
following the manufacturer’s recommendations. 
Polyclonal batches of the transduced RCC4 were 
then selected with constant concentration of 4µg/mL 
puromycin for four weeks and then maintained at 2µg/
mL for cell culture.
Knockdown of HIF1α in RCC4 using short hairpin 
RNA (shHIF1α NM_001530.x_1048s1c1, Sigma) was 
performed as described previously [50].
Western blot (WB)
WB was performed as described elsewhere [50]. 
Detailed information of the antibodies used for WB 
analysis is listed in Table 3.
RNA extraction and quantitative PCR
RNA was extracted from cultured cells or from 
two core punches of FFPE samples using Maxwell® 
16 LEV simplyRNA and RNA FFPE Purification 
Kit (Promega corporation,USA). RNA was reversely 
transcribed into cDNA using the High-Capacity cDNA 
Reverse Transcription Kit. RNA levels were determined 
by quantitative PCR using TaqMan® Gene Expression 
Assay on the ViiA7 Real-Time PCR System instrument 
(Applied Biosystems, United States). The probes 
used were Hs00184451 (VHL), Hs00153340 (TP53), 
Hs00355782 (p21), Hs00180269 (Bax), Hs00736699 
(Noxa), Hs00936377 (HIF1α) and Hs01026146 (HIF2α). 
The results were normalized to PPIA (Hs99999904) 
RNA level in each sample [51]. The results are shown as 
Relative Quantity (RQ).
Proliferation and apoptosis assays
A colorimetric Cell Proliferation ELISA BrdU assay 
(Roche diagnostics, Switzerland) and a Caspase-Glo® 3/7 
Assay System (Promega corporation, United States) was 
used to investigate the proliferative and apoptotic behavior 
of the established cell lines, respectively.
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Drug treatment
Camptothecin and Sunitinib (Selleck Chemicals, 
USA) were diluted in DMSO at 0.05 µM and 10 µM 
concentration, respectively, and applied to the cells alone 
or in combination for 48h at a final concentration of 0.3% 
DMSO following the manufacturer recommendation. 
The vehicle control with 0.3% DMSO was referred to as 
“mock”, and “mock VHL30” was used as a reference.
Statistics
Two-tailed Chi square, Fischer’s exact test and 
Student’s T-tests were performed using the program 
Graphpad prism 5.04 for Windows (GraphPad Software, 
San Diego California USA, www.graphpad.com).
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